clinical trial · NCT05667194
Phase 1 Trial of KH617
Sichuan Honghe Biotechnology Co., Ltd.·phase1·recruiting·n = 45
Advanced Solid TumorsKH617
brief summary
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
started
Dec 26, 2022
primary completion
Sep 1, 2030
completion
Aug 1, 2031
last updated
Nov 27, 2024
official title
A Phase 1 Study to Assess the Safety ,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of KH617 After SAD and MAD Administration for Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol